Prednisone (Synonyms: 1,2-Dehydrocortisone, NSC 10023) |
| Catalog No.GC16450 |
Glucocorticoid receptor agonist
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 53-03-2
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Prednisone (Adasone) is a synthetic corticosteroid agent that is particularly effective as an immunosuppressant compound.Target: OthersPrednisone is a synthetic corticosteroid drug that is particularly effective as an immunosuppressant drug. It is used to treat certain inflammatory diseases (such as moderate allergic reactions) and (at higher doses) some types of cancer, but has significant adverse effects. Because it suppresses the immune system, it leaves patients more susceptible to infections.Prednisone can also be used in the treatment of decompensated heart failure to potentiate renal responsiveness to diuretics, especially in heart failure patients with refractory diuretic resistance with large dose of loop diuretics. The mechanism is prednisone, as a glucocorticoid, can improve renal responsiveness to atrial natriuretic peptide by increasing the density of natriuretic peptide receptor type A in the renal inner medullary collecting duct, inducing a potent diuresis.
References:
[1]. RIEMER AD. Application of the newer corticosteroids to augment diuresis in congestive heart failure. Am J Cardiol. 1958 Apr;1(4):488-96.
[2]. Zhang H, et al. Prednisone adding to usual care treatment for refractory decompensated congestive heart failure. Int Heart J. 2008 Sep;49(5):587-95.
| Cell experiment [1]: | |
|
Cell lines |
Peripheral blood lymphocytes (PBL) or peripheral CD4+ and CD8+ T cell subsets |
|
Preparation method |
The solubility of this compound in DMSO is > 15.4 mg/mL. General tips for obtaining a higher concentration: Please warm the tube at 37 °C for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below - 20 °C for several months. |
|
Reacting condition |
10-3 ~ 10-12 M; 72, 96 and 120 hrs |
|
Applications |
Prednisone arrested PBL in the G1 phase of cell cycle, and inhibited IL-2 receptor (IL-2R) expression as well as IL-2 secretion. In phytohaemaglutinin (PHA)-activated human PBL, Prednisone significantly increased apoptosis. Moreover, Prednisone exhibited stronger apoptotic effect on CD8+ T lymphocytes than on CD4+ T lymphocytes. All these effects were shown in dose- and time-dependent manners. |
| Animal experiment [2]: | |
|
Animal models |
Male Wistar rats |
|
Dosage form |
5 mg/kg/d; p.o.; for 90 days |
|
Applications |
In Wistar rats, Prednisone significantly delayed learning and memory retention by 20%. Compared with the control group, the neuronal degeneration index in the Prednisone treatment group was 2 times higher in the prefrontal cortex, and about 10 times higher in the CA1 hippocampus. In addition, Prednisone substantially increased the number and cytoplasmic transformation of astrocytes, as well as isolectin-B4-labeled microglia cells in the prefrontal cortex. |
|
Other notes |
Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal. |
|
References: [1]. Lanza L, Scudeletti M, Puppo F, Bosco O, Peirano L, Filaci G, Fecarotta E, Vidali G, Indiveri F. Prednisone increases apoptosis in in vitro activated human peripheral blood T lymphocytes. Clin Exp Immunol. 1996 Mar;103(3):482-90. [2]. Ramos-Remus C, González-Castaeda RE, González-Perez O, Luquin S, García-Estrada J. Prednisone induces cognitive dysfunction, neuronal degeneration, and reactive gliosis in rats. J Investig Med. 2002 Nov;50(6):458-64. |
|
| Cas No. | 53-03-2 | SDF | |
| Synonyms | 1,2-Dehydrocortisone, NSC 10023 | ||
| Chemical Name | (8S,9S,10R,13S,14S,17R)-17-hydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-6,7,8,9,12,14,15,16-octahydrocyclopenta[a]phenanthrene-3,11-dione | ||
| Canonical SMILES | CC12CC(=O)C3C(C1CCC2(C(=O)CO)O)CCC4=CC(=O)C=CC34C | ||
| Formula | C21H26O5 | M.Wt | 358.43 |
| Solubility | ≥ 15.35mg/mL in DMSO | Storage | Store at 4°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 2.7899 mL | 13.9497 mL | 27.8995 mL |
| 5 mM | 558 μL | 2.7899 mL | 5.5799 mL |
| 10 mM | 279 μL | 1.395 mL | 2.7899 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 2 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *